Salesforce Climbs 22% in Six Months: Is the Stock Still Worth Buying?

Salesforce shares gained 22% over six months, while fiscal 2027 revenue guidance was raised to $46.10-$46.40 billion from $45.90-$46.20 billion. Q2 fiscal 2027 revenue rose 10.8% year over year to $11.35 billion; Agentforce ARR exceeded $1.5 billion, up more than 240%, and combined Agentforce and Data 360 ARR reached nearly $3.9 billion, up more than 210%. The article recommends buying the stock, citing AI adoption, stabilizing growth and a forward P/E valuation below sector averages; it also notes Informatica added $456 million to Q2 revenue.

Analysis

The investable question is not whether Agentforce usage is accelerating, but whether usage converts into durable, incremental paid workloads without eroding Salesforce’s existing seat-based economics. ARR and activity metrics are encouraging but do not disclose net expansion, discounting, customer-level deployment breadth, or contribution margins. AI agents could lift data consumption and platform attachment; they could also automate work currently priced by user seat, creating substitution risk over time.

Near term, acquisition contribution complicates the apparent growth inflection: reported revenue growth is not equivalent to organic acceleration. Longer contracts may improve visibility but can defer churn or mask weaker usage until renewal. The market may be underestimating execution and integration risk while over-crediting early AI activity as monetized demand. The article’s conflicting forward P/E comparisons also make the valuation argument unreliable without a consistent estimate set.

Over 1–3 months, the key catalysts are organic growth excluding Informatica, cRPO conversion, and evidence that Agentforce/Data 360 bookings translate into recurring revenue rather than pilots or bundled discounts. Over 6–18 months, the upside case is platform cross-sell and higher customer retention; the downside is seat compression, elevated integration costs, or AI revenue that fails to offset cannibalization. The bullish thesis weakens if organic subscription growth or cRPO decelerates, or if management signals weaker monetization or margins.

Key Decisions for Investors

• Consider a measured long CRM position, preferably staged rather than chasing the recent rally; add only if subsequent results show organic subscription growth and cRPO holding up while AI adoption converts into paid expansion.
• Do not treat Agentforce usage or ARR growth alone as proof of earnings leverage. Track paid deployments, net expansion, pricing/discounting, and operating-margin direction; these are the missing checks before sizing the AI thesis materially.
• For a relative-value expression, avoid a mechanical CRM-versus-peer short based on the article’s inconsistent P/E figures. Reassess CRM against ADBE, NOW, and ORCL using the same forward earnings period and organic growth definitions before initiating a pair.
• Falsification: reduce or exit the thesis if organic subscription growth and cRPO weaken across sequential reports, or if AI adoption rises without corresponding recurring revenue and margin contribution. Integration or guidance deterioration would also invalidate the near-term setup.